CHAIN Biotech appoints new Chief Executive

CHAIN announces the appointment of Dr Matthew Duchars as Chief Executive from the 1st of August 2022

Nottingham, UK- 20th of July 2022

CHAIN Biotechnology has strengthened its senior management team through the appointment of Dr Matthew Duchars.

Matthew is an experienced leader in vaccine development and manufacture with senior management roles at the Vaccine Manufacturing and Innovation Centre, Oxford (CEO), the Sabin Vaccine institute, Washington DC, USA (Senior Vice President, R&D) and with Emergent Biosolutions, Gaithersburg, MD, USA (Vice President, Product Development).

CHAIN Biotech has developed an innovative CADDTM platform which is based on living gut bacteria that form part of the microbiome. The bacteria produce functional molecules in the lower gastrointestinal tract where they have a positive impact on the gut microbiome and mucosal health. Engineering biology is used to add additional therapeutic functionality through the expression of specific antigenic peptides, which makes the CADDTM platform ideally suited for oral vaccines.

Matthew will replace CHAIN’s founder Dr Edward Green as Chief Executive with a focus on further developing the CADDTM platform for oral vaccination. Edward will remain on the Board, and act as Chief Scientific Advisor.

Dr Matthew Duchars said:

“I am excited to join the CHAIN team. I am greatly impressed by their expertise and highly innovative CADDTM platform technology with the potential to develop effective oral vaccines. The company has done a great job securing several strategic partnerships that bring both credibility and help de-risk drug development and manufacture”

Dr Nel Moore, Chair of CHAIN Biotech, said:

‘We are delighted to welcome Matthew to CHAIN’s leadership team. Matthew brings a wealth of experience in vaccine development and manufacture that complements our strain engineering and microbiology skills. I look forward to working closely with Matthew to develop our technology for oral vaccine applications, bringing benefit to patients and building shareholder value”


For more information please contact:
Edward Green, CHAIN Biotech
T: +44 (0)775 3610798 | E: [email protected]

CHAIN Biotechnology Ltd. MediCity, D6 Thane Road Nottingham, NG90 6BH

Notes to Editor


CHAIN Biotech is a UK SME, based in Nottingham, developing microbiome therapeutics. CHAIN has specialist expertise with anaerobic bacteria and bespoke strain engineering skills, enabling the expression of a wide range of therapeutic candidates in Clostridium. This expertise supports an innovative CADDTM platform for oral drug delivery. The technology is based on living bacteria that have been engineered to deliver specific therapeutic cargo to the lower gastrointestinal tract impacting on both the gut microbiota and gut mucosa.

The platform has broad clinical applicability depending on the selected cargo and been exemplified using peptide and metabolite candidates for treating inflammation, infection, and for immuno- modulation.

CHAIN’s microbiome therapeutics are low cost, scalable and stable with no cold-chain logistics, offering significant patient and societal benefits.

For more information, please visit:

CHAIN Biotechnology Ltd. MediCity, D6 Thane Road Nottingham, NG90 6BH